U-51605

• Description:

  U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) [1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  PGE synthase

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/u-51605.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(CCC/C=C\C[C@@H]1[C@H]([C@@]2([H])C[C@]1([H])N=N2)/C=C/CCCCCC)=O

• Molecular Formula:

  C20H32N2O2

• Molecular Weight:

  332.48

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Needleman P, Bryan B, Wyche A, et al. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions[J]. Prostaglandins, 1977, 14 (5) : 897-907.|[2]Mori A, Namekawa R, Hasebe M, et al. Involvement of prostaglandin I2 in nitric oxide-induced vasodilation of retinal arterioles in rats[J]. European Journal of Pharmacology, 2015, 764: 249-255.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [64192-56-9]